Press release no. 679 -  At its meeting of 22 December 2021, AIFA’s Technical Scientific Commission (CTS) approved the use of Novavax’s COVID-19 vaccine Nuvaxovid, making it available to people aged 18 years or over for the entire indication authorised by EMA. The vaccine is administered as a primary course of two doses, given three weeks apart.

As the CTS noted, available data on Nuvaxovid showed approximately 90% efficacy in preventing symptomatic COVID-19 even in the population aged over 64 years. The safety profile was positive, with predominantly local adverse reactions.